Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dual-target CAR-NK cells (Beijing Biotech)
- Development stage
- Unknown
- Lead developer
- Beijing Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an investigational, allogeneic, off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Beijing Biotech for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). The therapy utilizes NK cells derived from healthy donor cord blood, which are genetically engineered to express dual-target CAR constructs using a tandem OR-gate approach. These constructs target combinations of tumor-associated antigens, specifically mesothelin (MSLN), epidermal growth factor receptor (EGFR), and human epidermal growth factor receptor 2 (HER2). The engineered NK cells also express interleukin-15 (IL-15) to enhance in vivo survival and persistence and incorporate an inducible safety switch (iCasp9) to allow for controlled depletion of the cells if necessary. The therapy is currently being evaluated in a biomarker-guided Phase 1/2 clinical trial where patients receive a CAR-NK product matched to their specific tumor antigen profile.
- Other names
- dual-target CAR-NK cellsoff-the-shelf dual-target CAR-NK cellsMSLN/EGFR/HER2 CAR-NK cells
02
Targets
Beyond the preview
Go deeper on dual-target CAR-NK cells (Beijing Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dual-target CAR-NK cells (Beijing Biotech).